Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:advocacy |
required for administration
|
| gptkbp:approves |
adults in some countries
|
| gptkbp:associated_with |
reduction in mortality rates
reduced risk of severe forms of TB reduction in TB incidence |
| gptkbp:average_temperature |
2 to 8 ° C
|
| gptkbp:clinical_trial |
ongoing research
|
| gptkbp:clinical_use |
preventive measure
|
| gptkbp:contains |
live attenuated Mycobacterium bovis
|
| gptkbp:defense |
included in EPI
|
| gptkbp:developed_by |
gptkb:Camille_Guérin
gptkb:Albert_Calmette |
| gptkbp:first_introduced |
gptkb:1921
|
| gptkbp:global_presence |
over 100 countries
|
| gptkbp:has |
long history of use
|
| gptkbp:historical_significance |
first vaccine for a bacterial disease
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tuberculosis vaccine
|
| gptkbp:immunity_duration |
approximately 10 years
|
| gptkbp:influenced_by |
gptkb:scientific_research
public health policies |
| gptkbp:influences |
tuberculosis control efforts
|
| gptkbp:invention |
patented
|
| gptkbp:is |
a key component of TB prevention
|
| gptkbp:is_effective_against |
varies by population
latent tuberculosis infection pulmonary tuberculosis in adults |
| gptkbp:is_linked_to |
improved health outcomes
|
| gptkbp:is_recommended_for |
infants
children at risk |
| gptkbp:is_studied_for |
potential use in COVID-19
|
| gptkbp:is_studied_in |
various populations
|
| gptkbp:is_subject_to |
regulatory approvals
|
| gptkbp:is_vulnerable_to |
varies by region
live attenuated vaccine can affect uptake |
| gptkbp:part_of |
immunization schedules
TB control strategies |
| gptkbp:produced_by |
various manufacturers
|
| gptkbp:public_awareness |
important for vaccination campaigns
|
| gptkbp:requires |
cold chain logistics
booster doses in some cases |
| gptkbp:research_focus |
improving efficacy
|
| gptkbp:route_of_administration |
intradermal
|
| gptkbp:side_effect |
fever
lymphadenopathy rare complications local reaction |
| gptkbp:suitable_for |
HIV-positive individuals
|
| gptkbp:targets |
tuberculosis
|
| gptkbp:type |
BCG vaccine
|
| gptkbp:used_in |
mass vaccination campaigns
|
| gptkbp:bfsParent |
gptkb:Crucell
|
| gptkbp:bfsLayer |
5
|